Live Breaking News & Updates on Simone Angstmann Mehr|Page 6

Stay updated with breaking news from Simone angstmann mehr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03


Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03
Phase 2 Study Published in Cornea: The Journal of Cornea and External Disease ; Study Met Primary Endpoint in Patients with Highly Symptomatic Evaporative Dry Eye Disease Associated with Meibomian Gland Dysfunction Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. and Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced …
Phase 2 Study Published in
Cornea: The Journal of Cornea and External Disease ; Study Met Primary Endpoint in Patients with Highly Symptomatic Evaporative Dry Eye Disease Associated with
Meibomian Gland Dysfunction
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSETSX: BHC) (“Bausch Health” or the “Company”), and Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced the ....

United States , Baden Wuberg , United Kingdom , Christian Roesky , Lainie Keller , Novaliq Gmb , Joseph Tauber , Josephc Papa , Simone Angstmann Mehr , Arthur Shannon , Bausch Health Companies Inc , Bausch Health Investor Contact , Exchange Commission , Gmbh Co , Tauber Eye Center , Bausch Health Media Contact , Bausch Lomb Incorporated , Health Sciences , Bausch Health , Novaliq Inc , External Disease , Study Met Primary Endpoint , Meibomian Gland Dysfunction , Bausch Health Companies , Novaliq Gmbh , Kansas City ,